OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Organization: Oryzon Genomics S.A.

4 Projects | 2 Researchers | $2,370,000 Invested

2018

Oryzon Genomics S.A.

Roger Bullock, PhD, BA, MA

ETHERAL : Epigenetic THERapy in ALzheimer’s Disease . A multicenter, multinational, randomized, double-blind, placebo-controlled, 3-arm, 26 weeks parallel-group study to evaluate the safety, tolerability of ORY-2001 in patients with mild-moderate AD

  • Funding Amount: $1,500,000
  • Organization Type: Biotechnology/For Profit
  • Program: Clinical
  • Target: Epigenetics
  • Status: Closed

2016

Oryzon Genomics S.A.

Tamara Maes, PhD

Clinical development of a companion marker for treatment with the dual LSD1/MAO-B inhibitor ORY-2001

  • Funding Amount: $300,000
  • Organization Type: Biotechnology/For Profit
  • Program: Biomarkers
  • Target: Epigenetics
  • Status: Closed

2015

Oryzon Genomics S.A.

Tamara Maes, PhD

Preclinical development of ORY-2001, a dual LSD1/MAOB inhibitor for the treatment of Alzheimer disease.

  • Funding Amount: $270,000
  • Organization Type: Biotechnology/For Profit
  • Program: Drug Discovery
  • Target: Epigenetics
  • Status: Closed

2010

Oryzon Genomics S.A.

Tamara Maes, PhD

First In Class Modifying Disease Drugs for Alzheimer's Disease

  • Funding Amount: $300,000
  • Organization Type: Biotechnology/For Profit
  • Program: Drug Discovery
  • Target: Epigenetics
  • Status: Closed